LB-102

DRUG5 trials

Sponsors

LB Pharmaceuticals Inc.

Conditions

Bipolar I DisorderSchizophrenia

Phase 1

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

CompletedNCT04187560

LB Pharmaceuticals Inc.Schizophrenia

Start: 2020-01-22End: 2020-11-09Updated: 2020-12-10

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

CompletedNCT04588129

LB Pharmaceuticals Inc.Schizophrenia

Start: 2021-01-05End: 2021-11-15Updated: 2022-05-04

Phase 2

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

CompletedNCT06179108

LB Pharmaceuticals Inc.Schizophrenia

Start: 2023-11-29End: 2024-12-04Updated: 2025-10-22

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

RecruitingNCT07494305

LB Pharmaceuticals Inc.Bipolar I Disorder

Start: 2026-01-23End: 2028-02-01Target: 320Updated: 2026-07-27

Phase 3

52-week Open Label Safety-Tolerability Study

RecruitingNCT07369154

LB Pharmaceuticals Inc.Schizophrenia

Start: 2026-04-23End: 2029-04-01Target: 900Updated: 2026-09-09

Related Papers

Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.

2026-04-22

PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement

Neuropsychopharmacology2024-10-161 citations